Interstitial Lung Disease News

HONOLULU — Risk for mortality and hospitalization did not differ between patients with idiopathic pulmonary fibrosis taking 100 mg or 150 mg nintedanib twice daily, according to a real-world analysis presented at the CHEST Annual Meeting.

Patients with sarcoidosis receiving 40 mg per day of prednisolone had comparable rates of treatment failure and adverse effects to patients receiving 20 mg per day, according to a European Respiratory Society International Congress presentation.

Patients with systemic sclerosis-associated interstitial lung disease who receive nintedanib demonstrate a higher risk for malnutrition, compared with placebo, according to data published in Arthritis Care & Research.

Receiving an oral lysophosphatidic acid receptor 1 antagonist for 26 weeks lowered the rate of percent predicted FVC decline in progressive pulmonary fibrosis, according to a European Respiratory Society International Congress presentation.

SAN DIEGO — Rheumatologists should stratify patients with systemic sclerosis-associated interstitial lung disease into phenotypes in order to closely monitor those with progressing disease, according to a speaker here.

Given the rarity of pulmonary fibrosis, pulmonologists are constantly seeking to know more about the disease and advance research on treatment options.

The FDA granted orphan drug designation to zelasudil for treating patients with idiopathic pulmonary fibrosis, according to a press release from the drug’s manufacturer.

Patients with COVID-19-related acute respiratory distress syndrome undergoing transplantation had comparable, high survival rates to patients with COVID-19-related pulmonary fibrosis, according to results published in JAMA Surgery.

Nintedanib slows the deterioration of lung functionality in patients with limited cutaneous systemic sclerosis and interstitial lung disease, according to data published in Rheumatology.

The American College of Rheumatology “strongly recommends” against the use of glucocorticoids as a first-line therapy for interstitial lung disease in patients with systemic sclerosis-associated ILD, according to newly released guidelines.